ArticleFrontiers in pharmacology2026

Case Report: A successful rechallenge with aumolertinib after osimertinib-induced severe interstitial lung disease.

Hejing Bao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.